The DOI matches its Crossref record; 146 of the 147 references it cites were found in a registry or an index.
Aβ Oligomers – a decade of discovery
Open accessAbstract
Converging lines of evidence suggest that progressive accumulation of the amyloid β‐protein (Aβ) plays a central role in the genesis of Alzheimer’s disease, but it was long assumed that Aβ had to be assembled into extracellular amyloid fibrils to exert its cytotoxic effects. Over the past decade, data have emerged from the use of synthetic Aβ peptides, cell culture models, β‐amyloid precursor protein transgenic mice and human brain to suggest that pre‐fibrillar, diffusible assemblies of Aβ are also deleterious. Although the precise molecular identity of these soluble toxins remains unsettled, accumulating evidence suggests that soluble forms of Aβ are indeed the proximate effectors of synapse loss and neuronal injury. Here we review recent progress in understanding the role of soluble oligomers in Alzheimer’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“recent studies have shown that the soluble Aβ oligomers are more neurotoxic both in vitro and in vivo.5−8”
From Small Bifunctional Chelators That Do Not Disaggregate Amyloid β Fibrils Exhibit Reduced Cellular Toxicity (2014) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For the preformed Aβ42 fibrils, no significant cell toxicity was observed in either the absence or presence of Cu2+ (Figure 9, lanes 1 and 2), supporting the previously reported diminished toxicity of Aβ42 fibrils.5,7,54−56”
From Small Bifunctional Chelators That Do Not Disaggregate Amyloid β Fibrils Exhibit Reduced Cellular Toxicity (2014) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, recent in vivo studies have shown that soluble Aβ oligomers are more neurotoxic than amyloid plaques and most likely responsible for synaptic dysfunction and memory loss in AD.7–11”
From The effect of Cu2+ and Zn2+ on the Aβ42 peptide aggregation and cellular toxicity (2013) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“However, recent in vivo studies have shown that the soluble Aβ oligomers are possibly more neurotoxic than amyloid plaques,14–17 and are likely responsible for synaptic dysfunction and memory loss in AD patients and AD animal models.18–21”
From Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ42Peptide (2012) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“which was also shown to form neurotoxic soluble Aβ oligomers.18–20”
From Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ42Peptide (2012) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“This is confirmed by the decreased cell survival of 44±8% in presence of soluble Aβ42 oligomers (Figure 11, lane 2), supporting the increased neurotoxicity of Aβ42 oligomers versus Aβ42 fibrils.16,19”
From Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ42Peptide (2012) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“the Aβ42 peptide was employed in these studies because it was shown to form neurotoxic soluble Aβ oligomers.5,8,48”
From Small Bifunctional Chelators That Do Not Disaggregate Amyloid β Fibrils Exhibit Reduced Cellular Toxicity (2014) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 4×
“…performance in a hippocampaldependent contextual fear conditioning assay, decreased spine density in the dentate gyrus, and impairment of long-term potentiation (LTP) at ages long before the first apparent detection of Ab dodecamer (Dineley et al. 2002; Jacobsen et al. 2006; Lesne et al. 2006).”
BackgroundInfluentialRetractedCorder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Self-citationTriple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876 · cited 3×
“The initial cleavage leading to amyloid b-protein (Ab) production is mediated by the aspartyl protease, b-secretase (also called b-amyloid cleaving enzyme-1, BACE-1), and occurs immediately N-terminal to the Ab domain, simultaneously generating APPsb and the membranetethered C-terminal fragment, C99 (Vassar et al. 199…”
Background
Flagged first, then by citations
1 of the 147 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Selkoe D. J., 2003, Annu. Rev. Pharmacol. Toxicol., 545
- Shankar G. M., 2007, Natural oligomers of the Alzheimer amyloid beta‐protein induce hippocampal synapse loss but can be neutralized by antibodies and small molecules, J. Neurosci.
Cited by
Sorted by citations
Items 201–300 of 1,010
Zeller, M. V., Dias, D., Sebastião, A. M., & Valente, C. A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210268 · Cited by 179
Chung, E., Ji, Y., Sun, Y., Kascsak, R. J., Kascsak, R. B., Mehta, P. D., Strittmatter, S. M., & Wisniewski, T. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-130 · Cited by 152
Tau Oligomers: The Toxic Player at Synapses in Alzheimer’s Disease
Guerrero-Muñoz, M. J., Gerson, J., & Castillo-Carranza, D. L. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00464 · Cited by 168
Arbel‐Ornath, M., Hudry, E., Boivin, J. R., Hashimoto, T., Takeda, S., Kuchibhotla, K. V., Hou, S. S., Lattarulo, C. R., Belcher, A. M., Shakerdge, N. B., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0169-9 · Cited by 176
The Proton-Pump Inhibitor Lansoprazole Enhances Amyloid Beta Production
Badiola, N., Alcalde, V., Pujol, A., Munter, L. M., Multhaup, G., Lleó, A., Coma, M., Soler‐López, M., & Aloy, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058837 · Cited by 171
Angiotensins in Alzheimer's disease – friend or foe?
Kehoe, P. G., Miners, J. S., & Love, S. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.07.006 · Cited by 164
Li, Q., Zhao, H., Zhang, Z. F., Liu, Z. G., Pei, X., Wang, J. B., & Li, Y. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.07.014 · Cited by 165
Heat shock proteins in neurodegenerative disorders and aging
Leak, R. K. (2014) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-014-0243-9 · Cited by 175
Designing Peptide Inhibitors for Oligomerization and Toxicity of Alzheimer's β-Amyloid Peptide
Austen, B., Paleologou, K. E., Ali, S. A. E., Qureshi, M. M., Allsop, D., & El‐Agnaf, O. M. A. (2008) · Biochemistry · doi:10.1021/bi701415b · Cited by 170
Yumoto, S., Kakimi, S., Ohsaki, A., & Ishikawa, A. (2009) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2009.07.023 · Cited by 166
Regulated Formation of an Amyloid-like Translational Repressor Governs Gametogenesis
Berchowitz, L. E., Kabachinski, G., Walker, M. R., Carlile, T. M., Gilbert, W. V., Schwartz, T., & Amon, A. (2015) · Cell · doi:10.1016/j.cell.2015.08.060 · Cited by 162
Intraneuronal Aβ detection in 5xFAD mice by a new Aβ-specific antibody
Youmans, K. L., Tai, L. M., Kanekiyo, T., Stine Jr, W. B., Michon, S.-C., Nwabuisi-Heath, E., Manelli, A. M., Fu, Y., Riordan, S., Eimer, W. A., et al. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-8 · Cited by 164
Diversity of Amyloid-beta Proteoforms in the Alzheimer’s Disease Brain
Wildburger, N. C., Esparza, T. J., LeDuc, R. D., Fellers, R. T., Thomas, P. M., Cairns, N. J., Kelleher, N. L., Bateman, R. J., & Brody, D. L. (2017) · Scientific Reports · doi:10.1038/s41598-017-10422-x · Cited by 164
Taylor, M., Moore, S., Mayes, J., Parkin, E. T., Beeg, M., Canovi, M., Gobbi, M., Mann, D. M. A., & Allsop, D. (2010) · Biochemistry · doi:10.1021/bi100144m · Cited by 166
Probing conformational dynamics in biomolecules via chemical exchange saturation transfer: a primer
Vallurupalli, P., Sekhar, A., Yuwen, T., & Kay, L. E. (2017) · Journal of Biomolecular NMR · doi:10.1007/s10858-017-0099-4 · Cited by 163
γ-Secretase Modulators as Potential Disease Modifying Anti-Alzheimer’s Drugs
Oehlrich, D., Berthelot, D., & Gijsen, H. J. M. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101168r · Cited by 163
Amyloid‐β oligomers set fire to inflammasomes and induce Alzheimer's pathology
Salminen, A., Ojala, J. O., Suuronen, T., Kaarniranta, K., & Kauppinen, A. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00496.x · Cited by 167
Scuderi, C., Steardo, L., & Esposito, G. (2014) · Phytotherapy Research · doi:10.1002/ptr.5095 · Cited by 161
The physiology of the β‐amyloid precursor protein intracellular domain AICD
Pardossi‐Piquard, R., & Checler, F. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07475.x · Cited by 159
Darnell, G. D., Orgel, J. P. R. O., Pahl, R., & Meredith, S. C. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.09.023 · Cited by 162
Grimm, M. O. W., Mett, J., Stahlmann, C. P., Haupenthal, V. J., Zimmer, V. C., & Hartmann, T. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00098 · Cited by 170
Mahmoudi, M., Quinlan-Pluck, F., Monopoli, M. P., Sheibani, S., Vali, H., Dawson, K. A., & Lynch, I. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300196n · Cited by 162
Biological markers of amyloid β-related mechanisms in Alzheimer's disease
Hampel, H. J., Shen, Y., Walsh, D. M., Aisen, P. S. S., Shaw, L. M., Zetterberg, H., Trojanowski, J. Q., & Blennow, K. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.024 · Cited by 162
Self-citationKim, Y., Hwang, C. J., Lee, H. P., Kim, C. S., Son, D. J., Ham, Y. W., Hellström, M., Han, S., Kim, H. S., Park, E. K., et al. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.01.025 · Cited by 162
Feng, X., Liang, N., Zhu, D., Gao, Q., Peng, L., Dong, H., Yue, Q., Liu, H., Bao, L., Zhang, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059888 · Cited by 160
Wu, J., Breydo, L., Isas, J. M., Lee, J., Kuznetsov, Y. G., Langen, R., & Glabe, C. G. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.069542 · Cited by 163
Routes, destinations and delays: recent advances in AMPA receptor trafficking
Henley, J. M., Barker, E. A., & Glebov, O. O. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2011.02.004 · Cited by 173
Amyloid β-protein and beyond: the path forward in Alzheimer’s disease
Walsh, D. M., & Selkoe, D. J. (2020) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2020.02.003 · Cited by 164
Self-citationApolipoprotein E, not fibrillar β-amyloid, reduces cerebral glucose metabolism in normal aging
Jagust, W. J., Landau, S. M., & Initiative, F. T. A. D. N. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.3266-12.2012 · Cited by 162
Calcium channel blockers and dementia
Nimmrich, V., & Eckert, A. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12240 · Cited by 156
Cukalevski, R., Yang, X., Meisl, G., Weininger, U., Bernfur, K., Frohm, B., Knowles, T. P. J., & Linse, S. S. (2015) · Chemical Science · doi:10.1039/c4sc02517b · Cited by 161
Neuroimaging and Other Biomarkers for Alzheimer's Disease: The Changing Landscape of Early Detection
Risacher, S. L., & Saykin, A. J. (2013) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050212-185535 · Cited by 163
Tauopathy with paired helical filaments in an aged chimpanzee
Rosen, R. F., Farberg, A. S., Gearing, M., Dooyema, J., M. Long, P., Anderson, D. C., Davis‐Turak, J., Coppola, G., Geschwind, D. H., Paré, J., et al. (2008) · Journal of Comparative Neurology · doi:10.1002/cne.21744 · Cited by 153
Ligand for Translocator Protein Reverses Pathology in a Mouse Model of Alzheimer's Disease
Barron, A. M., García‐Segura, L. M., Caruso, D., Jayaraman, A., Lee, J.-W., Melcangi, R. C., & Pike, C. J. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.1350-13.2013 · Cited by 159
Rushworth, J. V., Jarosz-Griffiths, H., Watt, N. T., & Hooper, N. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.400358 · Cited by 157
Vitamin A and Alzheimer's disease
Ono, K., & Yamada, M. (2011) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/j.1447-0594.2011.00786.x · Cited by 156
Mormino, E. C., Brandel, M. G., Madison, C. M., Marks, S. M., Baker, S. L., & Jagust, W. J. (2011) · Cerebral Cortex · doi:10.1093/cercor/bhr255 · Cited by 151
Picone, P., Bondì, M. L., Picone, P., Bondì, M. L., Montana, G., Bruno, A., Pitarresi, G. L., Giammona, G., & Carlo, M. D. (2009) · Free Radical Research · doi:10.1080/10715760903214454 · Cited by 156
Zussy, C., Brureau, A., Delair, B., Marchal, S., Keller, E., IXART, G., Naert, G., Meunier, J., Chevallier, N., Maurice, T., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.03.021 · Cited by 154
Sarroukh, R., Cerf, E., Derclaye, S., Dufrêne, Y. F., Goormaghtigh, E., Ruysschaert, J., & Raussens, V. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0529-x · Cited by 160
Alzheimer’s disease: How metal ions define β-amyloid function
Kepp, K. P. (2017) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2017.05.007 · Cited by 154
Inclusion bodies: Specificity in their aggregation process and amyloid-like structure
Morell, M., Bravo, R., Espargaró, A., Sisquella, X., Avilés, F. X., Fernàndez‐Busquets, X., & Ventura, S. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.06.007 · Cited by 152
Costanzo, M., & Zurzolo, C. (2013) · Biochemical Journal · doi:10.1042/bj20121898 · Cited by 161
Amyloid β-Induced Nerve Growth Factor Dysmetabolism in Alzheimer Disease
Bruno, M. A., León, W., Fragoso, G., Mushynski, W. E., Almazán, G., & Cuello, A. C. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181aed9e6 · Cited by 152
Multiple events lead to dendritic spine loss in triple transgenic Alzheimer’s disease mice
Bittner, T., Fuhrmann, M., Burgold, S., Ochs, S. M., Hoffmann, N., Mitteregger, G., Kretzschmar, H., LaFerla, F. M., & Herms, J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015477 · Cited by 149
Sehlin, D., Englund, H., Simu, B., Karlsson, M., Ingelsson, M., Nikolajeff, F. K., Lannfelt, L., & Pettersson, F. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032014 · Cited by 150
Debnath, K., Pradhan, N., Singh, B. K., Jana, N. R., & Jana, N. R. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b06510 · Cited by 149
Stefanovski, L., Triebkorn, P., Spiegler, A., Díaz-Cortés, M.-A., Solodkin, A., Jirsa, V., McIntosh, A. R., Ritter, P., & Initiative, A. D. N. (2019) · Frontiers in Computational Neuroscience · doi:10.3389/fncom.2019.00054 · Cited by 145
Neuronal Production of Transthyretin in Human and Murine Alzheimer's Disease: Is It Protective?
Li, X., Masliah, E., Reixach, N., & Buxbaum, J. N. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.2417-11.2011 · Cited by 147
Relevance of Transgenic Mouse Models to Human Alzheimer Disease
Morrissette, D. A., Parachikova, A. I., Green, K. N., & LaFerla, F. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800030200 · Cited by 150
Harris, J. A., Devidze, N., Halabisky, B., Lo, I., Thwin, M. T., Yu, G.-Q., Bredesen, D. E., Masliah, E., & Mucke, L. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5341-09.2010 · Cited by 146
Terpenoids as Potential Anti-Alzheimer’s Disease Therapeutics
Yoo, K.-Y., & Park, S. (2012) · Molecules · doi:10.3390/molecules17033524 · Cited by 151
Benilova, I., Gallardo, R. U., Ungureanu, A.-A., Cano, V. C., Snellinx, A., Ramakers, M., Bartic, C., Rousseau, F., Schymkowitz, J. W. H., & Strooper, B. D. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.599027 · Cited by 151
van Rossum, I. A., Vos, S. J. B., Handels, R. L. H., & Visser, P. J. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-091606 · Cited by 148
Ono, K., Condron, M. M., & Teplow, D. B. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.086496 · Cited by 150
Biomarkers in Alzheimer's disease drug development
Blennow, K. (2010) · Nature Medicine · doi:10.1038/nm.2221 · Cited by 145
Long-term immunomodulatory effect of amniotic stem cells in an Alzheimer's disease model
Kim, K.-S., Kim, H. S., Park, J.-M., Kim, H. W., Park, M., Lee, H., Lim, D. S., Lee, T. H., Chopp, M., & Moon, J. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.03.029 · Cited by 144
Cognition, glucose metabolism and amyloid burden in Alzheimer's disease
Furst, A. J., Rabinovici, G. D., Rostomian, A. H., Steed, T., Alkalay, A., Racine, C. A., Miller, B. L., & Jagust, W. J. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.011 · Cited by 153
The Biological Function of the Prion Protein: A Cell Surface Scaffold of Signaling Modules
Linden, R. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00077 · Cited by 151
D’Angelo, B., Santucci, S., Benedetti, E., Loreto, S. D., Phani, R., Falone, S., Amicarelli, F., Cerù, M. P., & Cimini, A. (2009) · Current Nanoscience · doi:10.2174/157341309788185523 · Cited by 142
Meilandt, W. J., Cissé, M., Ho, K., Wu, T. Z., Esposito, L., Scearce-Levie, K. A., Cheng, I. H.-J., Yu, G.-Q., & Mucke, L. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.2984-08.2009 · Cited by 144
Chan, K., Lam, K. S. L., Cheng, O.-Y., Kwan, J., Ho, P. W., Cheng, K. K. Y., Chung, S. K., Ho, J. W.-M., Guo, V. Y., & Xu, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052354 · Cited by 143
Na, K-ATPase α3 is a death target of Alzheimer patient amyloid-β assembly
Ohnishi, T., Yanazawa, M., Sasahara, T., Kitamura, Y., Hiroaki, H., Fukazawa, Y., Kii, I., Nishiyama, T., Kakita, A., Takeda, H., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421182112 · Cited by 141
Askanas, V., Engel, W. K., & Nogalska, A. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00290.x · Cited by 139
Nimmrich, V., & Ebert, U. (2009) · Reviews in the Neurosciences · doi:10.1515/revneuro.2009.20.1.1 · Cited by 139
Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review
Berlanga‐Acosta, J., Guillén, G. E., Rodríguez-Rodríguez, N., Bringas-Vega, M. L., García-del-Barco-Herrera, D., Berlanga-Saez, J. O., Ojalvo, A. G., Valdés-Sosa, M. J., & Valdes-Sosa, P. A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.560375 · Cited by 143
Yu, J., Gattoni-Celli, M., Zhu, H., Bhat, N. R., Sambamurti, K., Gattoni‐Celli, S., & Kindy, M. S. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101986 · Cited by 141
CREB expression mediates amyloid β-induced basal BDNF downregulation
Rosa, E., & Fahnestock, M. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.04.014 · Cited by 138
Glutamatergic synaptic plasticity and dysfunction in Alzheimer disease: Emerging mechanisms
Benarroch, E. E. (2018) · Neurology · doi:10.1212/wnl.0000000000005807 · Cited by 115
Man, B. Y.-W., Chan, H., Leung, C., Chan, D. S., Bai, L., Jiang, Z., Li, H., & Ma, D. (2011) · Chemical Science · doi:10.1039/c0sc00636j · Cited by 136
Hampel, H. J., Lista, S., & Khachaturian, Z. S. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.05.2116 · Cited by 142
The effect of Cu2+ and Zn2+ on the Aβ42 peptide aggregation and cellular toxicity
Sharma, A. K., Pavlova, S. T., Kim, J., Kim, J., & Mirica, L. M. (2013) · Metallomics · doi:10.1039/c3mt00161j · Cited by 135
Rosenblum, W. I. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.10.085 · Cited by 142
Vauzour, D. (2013) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.6473 · Cited by 139
The link between altered cholesterol metabolism and Alzheimer's disease
Gamba, P., Testa, G., Sottero, B., Gargiulo, S., Poli, G., & Leonarduzzi, G. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06513.x · Cited by 141
Autophagy Dysfunction in Alzheimer’s Disease: Mechanistic Insights and New Therapeutic Opportunities
Di Meco, A., Curtis, M. E., Lauretti, E., & Praticò, D. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.05.008 · Cited by 133
Mechanisms for the Insertion of Toxic, Fibril-like β-Amyloid Oligomers into the Membrane
Jang, H., Connelly, L. S., Arce, F. T., Ramachandran, S., Kagan, B. L., Lal, R., & Nussinov, R. (2012) · Journal of Chemical Theory and Computation · doi:10.1021/ct300916f · Cited by 134
Animal models of Alzheimer disease: historical pitfalls and a path forward
Cavanaugh, S. E. (2014) · ALTEX · doi:10.14573/altex.1310071 · Cited by 132
Carrero, I., Gonzalo, M. R., Martin, B., Sanz-Anquela, J. M., Arévalo-Serrano, J., & Gonzalo-Ruiz, A. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.05.004 · Cited by 132
RETRACTED: Cognitive effects of cell-derived and synthetically derived Aβ oligomers
Reed, M. N., Hofmeister, J. J., Jungbauer, L. M., Welzel, A. T., Yu, C., Sherman, M. A., Lesné, S., LaDu, M. J., Walsh, D. M., Ashe, K. H., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.11.007 · Cited by 135
Self-citationRetractedAlzheimer's disease; taking the edge off with cannabinoids?
Campbell, V. A., & Gowran, A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707446 · Cited by 132
Alzheimer disease and platelets: how’s that relevant
Catricalà, S., Torti, M., & Ricevuti, G. (2012) · Immunity & Ageing · doi:10.1186/1742-4933-9-20 · Cited by 132
Seizures in Alzheimer’s disease
Born, H. A. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.11.051 · Cited by 139
Alzheimer's disease: insights from Drosophila melanogaster models
Moloney, A. M., Sattelle, D. B., Lomas, D. A., & Crowther, D. C. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2009.11.004 · Cited by 135
Alzheimer’s disease as oligomeropathy
Ono, K. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2017.08.010 · Cited by 129
The Role and Therapeutic Targeting of α-, β- and γ-Secretase in Alzheimer's Disease
MacLeod, R., Hillert, E., Cameron, R. T., & Baillie, G. S. (2015) · Future Science OA · doi:10.4155/fso.15.9 · Cited by 136
Molecular and cellular pathophysiology of preclinical Alzheimer’s disease
Mufson, E. J., Ikonomović, M. D., Counts, S., Perez, S. E., Malek‐Ahmadi, M. H., Scheff, S. W., & Ginsberg, S. D. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.05.030 · Cited by 134
Rocha-Souto, B. D., Scotton, T. C., Coma, M., Serrano‐Pozo, A., Hashimoto, T., Serenó, L., Rodríguez, M., Sánchez, B., Hyman, B. T., & Gómez‐Isla, T. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318217a118 · Cited by 138
Treatment Strategies Targeting Amyloid -ProteinPreprint
Schenk, D., Basi, G. S., & Pangalos, M. N. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006387 · Cited by 131
Mechanism mediating oligomeric Aβ clearance by naïve primary microglia
Yang, C.-N., Shiao, Y.-J., Shie, F.-S., Guo, B.-S., Chen, P.-H., Cho, C.-Y., Chen, Y.-J., Huang, F.-L., & Tsay, H.-J. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.01.005 · Cited by 117
Costa, R., Ferreira-da-Silva, F., Saraiva, M., & Cardoso, I. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002899 · Cited by 128
Developmental vulnerability of synapses and circuits associated with neuropsychiatric disorders
Penzes, P., Buonanno, A., Passafaro, M., Sala, C., & Sweet, R. A. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12261 · Cited by 125
Immunotherapy for Alzheimer‘s Disease: From Anti-β-Amyloid to Tau-Based Immunization Strategies
Panza, F., Frisardi, V., Solfrizzi, V., Imbimbo, B. P., Logroscino, G., Santamato, A., Greco, A., Seripa, D., & Pilotto, A. (2012) · Immunotherapy · doi:10.2217/imt.11.170 · Cited by 130
Koelsch, G. (2017) · Molecules · doi:10.3390/molecules22101723 · Cited by 128
NFκB-dependent Control of BACE1 Promoter Transactivation by Aβ42
Buggia-Prévot, V., Sévalle, J., Roßner, S., & Checler, F. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m706579200 · Cited by 129
Role of glial cells in the formation and maintenance of synapses
Pfrieger, F. W. (2010) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.11.002 · Cited by 124
Can we prevent Alzheimer's disease? Secondary “prevention” trials in Alzheimer's disease
Carrillo, M. C., Brashear, H. R., Logovinsky, V., Ryan, J. M., Feldman, H., Siemers, E., Abushakra, S. R., Hartley, D. M., Petersen, R. C., Khachaturian, A. S., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.12.004 · Cited by 128
Alzheimer’s disease due to loss of function: A new synthesis of the available data
Kepp, K. P. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.06.004 · Cited by 123
Shankar, G. M., Leissring, M. A., Adame, A., Sun, X., Spooner, E., Masliah, E., Selkoe, D. J., Lemere, C. A., & Walsh, D. M. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.021 · Cited by 126
Self-citationLigand Binding Thermodynamics in Drug Discovery: Still a Hot Tip?
Geschwindner, S., Ulander, J., & Johansson, P. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501511f · Cited by 124
Metadata
- Authors
- Walsh, D. M., & Selkoe, D. J.
- Affiliations
- University College Dublin (IE)
- Brigham and Women's Hospital (US)
- Corresponding author
- Walsh, Dominic M.
- Selkoe, Dennis J.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2007-01-04
- Volume
- 101
- Issue
- 5
- Pages
- 1172-1184
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1981458288
- Cited by
- 1,938
- References
- 147
- Citations by year
- 2026: 48 · 2025: 36 · 2024: 46 · 2023: 47 · 2022: 50 · 2021: 63 · 2020: 76 · 2019: 81 · 2018: 81 · 2017: 109 · 2016: 120 · 2015: 136 · 2014: 134 · 2013: 159 · 2012: 167
- FWCI
- 14.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neurochemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Foundation for Neurologic Diseases
- Wellcome Trust (067660)
- National Institutes of Health
- National Institute on Aging (AG-06173)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta oligomers, Alzheimer's disease, soluble amyloid-beta, synaptic loss, neuronal injury, amyloid fibrils, amyloid precursor protein, transgenic mouse model
- MeSH terms
- Alzheimer Disease, Humans, Male, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Protein Structure, Secondary
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
